Why Tata 1mg thinks speed is the wrong bet in pharma
Tata 1mg just reported revenue of nearly 3,000 crore rupees for the last financial year, roughly ten times what it earned when Tata took control, and it is turning a profit while much of the sector bleeds cash. In an e-pharmacy market obsessed with 10-minute delivery and deep discounts, 1mg won by doing the opposite.…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
Similar episodes from other shows
More like Daybreak →
Indian pharma: lofty aims in the midst of chaos
How can India’s pharma companies survive under Trump’s uncertainty?
The Chinese Cancer Fix
Overhauling drugs law, Maha's new bike taxi rules, and Tata Sons' chairman
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.